Thermalin, Inc. is developing next-generation insulin solutions for people with Type 1 (T1D) and Type 2 diabetes (T2D). Thermalin’s pioneering science alters the insulin molecule to achieve greater therapeutic performance.

Portal Instruments is developing a unique platform technology to transform the delivery of modern medicines and improve the patient experience. Portal’s patented technology enables the precise delivery of the exact amount of drug at the desired tissue depth irrespective of drug viscosity and composition; particularly important for today’s new biological drugs. The company’s delivery mechanism is silent, painless, and highly customizable across a large variety of medical, animal, agricultural, and cosmetic applications.

Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world’s most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes.

MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company's first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.

DiCE’s unique technology platform leverages directed evolution to select and optimize low molecular weight compounds against any target. The DiCE platform’s capabilities include the potential to unlock protein-protein interfaces that were previously unreachable for oral therapies.